1. Home
  2. CVBF vs LQDA Comparison

CVBF vs LQDA Comparison

Compare CVBF & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CVB Financial Corporation

CVBF

CVB Financial Corporation

HOLD

Current Price

$20.52

Market Cap

2.8B

Sector

Finance

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$38.14

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CVBF
LQDA
Founded
1974
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.1B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
CVBF
LQDA
Price
$20.52
$38.14
Analyst Decision
Buy
Strong Buy
Analyst Count
3
10
Target Price
$24.17
$38.60
AVG Volume (30 Days)
1.4M
1.7M
Earning Date
01-21-2026
03-18-2026
Dividend Yield
3.89%
N/A
EPS Growth
5.58
N/A
EPS
1.52
N/A
Revenue
$518,957,999.00
$69,216,000.00
Revenue This Year
$20.70
$993.31
Revenue Next Year
$15.44
$219.14
P/E Ratio
$13.52
N/A
Revenue Growth
2.80
343.41
52 Week Low
$16.01
$11.26
52 Week High
$21.48
$46.67

Technical Indicators

Market Signals
Indicator
CVBF
LQDA
Relative Strength Index (RSI) 51.16 49.29
Support Level $20.43 $38.88
Resistance Level $21.48 $40.95
Average True Range (ATR) 0.52 2.30
MACD -0.01 -0.76
Stochastic Oscillator 45.37 11.23

Price Performance

Historical Comparison
CVBF
LQDA

About CVBF CVB Financial Corporation

CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: